Walleye Capital
ALXN

Walleye Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Walleye Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-66,350
Closed -$12.2M – 2045
2021
Q2 		$12.2M Buy
66,350
+25,983
+64% +$4.46M 0.42% 16
2021
Q1 		$6.17M Buy
40,367
+7,614
+23% +$1.18M 0.36% 37
2020
Q4 		$5.12M Buy
32,753
+30,332
+1,253% +$3.9M 0.34% 37
2020
Q3 		$277K Buy
+2,421
New +$261K 0.03% 522
2020
Q2 		– Sell
-15,446
Closed -$1.39M – 1105
2020
Q1 		$1.39M Sell
15,446
-2,960
-16% -$291K 0.31% 89
2019
Q4 		$1.99M Buy
18,406
+17,347
+1,638% +$1.86M 0.13% 199
2019
Q3 		$103K Buy
1,059
+859
+430% +$96.8K 0.01% 1431
2019
Q2 		$26K Hold
200
– – ﹤0.01% 1495
2019
Q1 		$27K Buy
+200
New +$24.9K ﹤0.01% 1315
2018
Q3 		$295K Buy
+2,125
New +$267K 0.14% 178

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Walleye Capital's ALXN Position: Q3 2021 in Review

Walleye Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 66,350 shares — an estimated $12.2M sold.

Walleye Capital first reported a position in ALXN in Q3 2018 and held it in 10 quarters. The position peaked at $12.2M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Walleye Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Walleye Capital sold 66,350 Alexion Pharmaceuticals shares in Q3 2021, an estimated $12.2M.
  • Walleye Capital first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 10 quarters.
  • Walleye Capital's Alexion Pharmaceuticals position peaked at $12.2M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Walleye Capital's 13F filing for Q3 2021, filed 15 Nov 2021.